Dr. Todd Morgan

And so that's a great study. And that really justifies the role of PSMA PET in this setting. And so, right, so we need to recognize these patients. We need to keep track of them because this is another like piece of tantalizing music data that I've seen unpublished and I haven't seen the real details yet. So I can only give like a small headline and hopefully Tudor Borza doesn't kill me.

And so that's a great study. And that really justifies the role of PSMA PET in this setting. And so, right, so we need to recognize these patients. We need to keep track of them because this is another like piece of tantalizing music data that I've seen unpublished and I haven't seen the real details yet. So I can only give like a small headline and hopefully Tudor Borza doesn't kill me.

And so that's a great study. And that really justifies the role of PSMA PET in this setting. And so, right, so we need to recognize these patients. We need to keep track of them because this is another like piece of tantalizing music data that I've seen unpublished and I haven't seen the real details yet. So I can only give like a small headline and hopefully Tudor Borza doesn't kill me.

But like a lot of patients are lost to follow up after prostatectomy. And so we, you know, we don't necessarily always have great mechanisms.

But like a lot of patients are lost to follow up after prostatectomy. And so we, you know, we don't necessarily always have great mechanisms.

But like a lot of patients are lost to follow up after prostatectomy. And so we, you know, we don't necessarily always have great mechanisms.

for keeping track of patients and we have to in primary care docs are managing a million different things and putting this on PCPs is really challenging when the report from you know PSA test reports back less than four or three years normal and not every patient understands the nuances and not every primary care doc understands those nuances and it's totally understandable so we have to be able to just keep track of our patients to be able to entertain any of this guideline-based care.

for keeping track of patients and we have to in primary care docs are managing a million different things and putting this on PCPs is really challenging when the report from you know PSA test reports back less than four or three years normal and not every patient understands the nuances and not every primary care doc understands those nuances and it's totally understandable so we have to be able to just keep track of our patients to be able to entertain any of this guideline-based care.

for keeping track of patients and we have to in primary care docs are managing a million different things and putting this on PCPs is really challenging when the report from you know PSA test reports back less than four or three years normal and not every patient understands the nuances and not every primary care doc understands those nuances and it's totally understandable so we have to be able to just keep track of our patients to be able to entertain any of this guideline-based care.

Ah, bingo. Thank you. Yes. That's a, it's really, really important. And so that's, so that's like the, the clinical scenario, I think that people understandably struggle with, which is like patient has a PSA of 0.2 and then maybe it's 0.3 and then you get the PSMA PET and it's negative.

Ah, bingo. Thank you. Yes. That's a, it's really, really important. And so that's, so that's like the, the clinical scenario, I think that people understandably struggle with, which is like patient has a PSA of 0.2 and then maybe it's 0.3 and then you get the PSMA PET and it's negative.

Ah, bingo. Thank you. Yes. That's a, it's really, really important. And so that's, so that's like the, the clinical scenario, I think that people understandably struggle with, which is like patient has a PSA of 0.2 and then maybe it's 0.3 and then you get the PSMA PET and it's negative.

And so some people might reasonably say, well, let's just hold off and let's, you know, we'll wait till the PET's positive. And then, well then, well, now we got metastatic disease that we're waiting for.

And so some people might reasonably say, well, let's just hold off and let's, you know, we'll wait till the PET's positive. And then, well then, well, now we got metastatic disease that we're waiting for.

And so some people might reasonably say, well, let's just hold off and let's, you know, we'll wait till the PET's positive. And then, well then, well, now we got metastatic disease that we're waiting for.

And, you know, until we have, Studies that have answered that question, like negative PSMA PET, we have tons of data to support the role of salvage radiation in this setting. PSMA PET's only a handful of years old. So we need to fall back on where we really do have level one evidence.

And, you know, until we have, Studies that have answered that question, like negative PSMA PET, we have tons of data to support the role of salvage radiation in this setting. PSMA PET's only a handful of years old. So we need to fall back on where we really do have level one evidence.

And, you know, until we have, Studies that have answered that question, like negative PSMA PET, we have tons of data to support the role of salvage radiation in this setting. PSMA PET's only a handful of years old. So we need to fall back on where we really do have level one evidence.

Yeah, I mean, we're getting better, right? The surgeries are getting better, without a doubt. It's a difficult surgery, but we're getting better at it. And we really finally understand this debate of adjuvant versus salvage radiation. And so we know what to do. And when I look at these guidelines, I mean, a lot of it is really well supported by high-level studies.

Yeah, I mean, we're getting better, right? The surgeries are getting better, without a doubt. It's a difficult surgery, but we're getting better at it. And we really finally understand this debate of adjuvant versus salvage radiation. And so we know what to do. And when I look at these guidelines, I mean, a lot of it is really well supported by high-level studies.